Abstract
Purpose: Recently, recombinant human erythropoietin (rhEPO) was introduced for the management of anemia in malignancy. To identify an indicator for a favourable response to rhEPO, 28 anaemic cancer patients undergoing chemotherapy and treated with rhEPO were evaluated. Methods: Patients were classified into responder (16 of 28, 57%) and nonresponder (12 of 28, 43%) groups according to their responses to rhEPO therapy (response being defined as an increase in Hb level of >2 g/dl from baseline without blood transfusion). Results: Treatment with rhEPO showed significant improvements in the red blood cell (RBC) count, haemoglobin (Hb), packed cell volume (PCV), and reticulocyte count (ret. count) after 4 weeks. Upon analysing the baseline value of the EPO level and the corrected ret.count in these two groups, we found that the ratio of the EPO level and the corrected ret.count (EPO/ret.count) demonstrated a statistical significance (P = 0.03) in the prediction of response to rhEPO therapy. This ratio showed a sensitivity of 87.5%, specificity of 66.7%, and overall accuracy of 78.6%. Conclusion: Our study suggested that the baseline ratio of EPO/ret.count should be used as an indicator for a favourable response to rhEPO therapy. J. Clin. Lab. Anal. 15:260–266, 2001. © 2001 Wiley‐Liss, Inc.
Keywords: baseline EPO level, corrected reticulocyte count, erythropoietin therapy, anaemia in malignancy
REFERENCES
- 1. Spivak JL. 1994. Cancer‐related anaemia: its causes and characteristics. Semin Oncol 21(2 Suppl 3):3–8. [PubMed] [Google Scholar]
- 2. Cash JM, Sears DA. 1989. Anaemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med 87:638–644. [DOI] [PubMed] [Google Scholar]
- 3. Krantz SB. 1994. Pathogenesis and treatment of the anaemia of chronic diseases. Am J Med Sci 307:353–359. [DOI] [PubMed] [Google Scholar]
- 4. Reizenstein P. 1979. The haemetological stress syndrome. Br J Haematol 43:329–334. [DOI] [PubMed] [Google Scholar]
- 5. Vreugdenhil G, Swaak AJ. 1990. Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment. Rheumatol Int 9:243–257. [DOI] [PubMed] [Google Scholar]
- 6. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. 1990. Decreased erythropoietin response in patients with the anaemia of cancer. N Engl J Med 322:1689–1692. [DOI] [PubMed] [Google Scholar]
- 7. Spivak JL. 1994. Recombinant human erythropoietin and the anaemia of cancer. Blood 84:997–1004. [PubMed] [Google Scholar]
- 8. Lee GR. 1983. The anaemia of chronic disease. Sem Haematol 20:61–80. [PubMed] [Google Scholar]
- 9. Spivak JL, Barnes DC, Fuchs E, et al. 1989. Serum immunoreactive erythropoietin in HIV infected patients. JAMA 261:3104–3107. [PubMed] [Google Scholar]
- 10. Henry DH, Abels RI. 1994. Recombinant human erythropoietin in the treatment of cancer and chemotherapy‐induced anaemia: results of double‐blind and open‐labeled follow‐up studies. Semin Oncol 21(2 Suppl 3):21–28. [PubMed] [Google Scholar]
- 11. Skillings JR, Sridhar FG, Wong C, et al. 1993. The frequency of red cell transfusion for anaemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16:22–25. [DOI] [PubMed] [Google Scholar]
- 12. Seidl S, Kuhnl P. 1987. Transmission of disease by blood transfusion. World J Surg 11:30–35. [DOI] [PubMed] [Google Scholar]
- 13. Walker RH. 1987. Transfusion risks. Am J Clin Pathol 88:374–378. [DOI] [PubMed] [Google Scholar]
- 14. Case DC Jr, Bukowski RM, Carey RW. 1993. Recombinant human erythropoietin therapy combination chemotherapy. J Natl Cancer Inst 85:801–806. [DOI] [PubMed] [Google Scholar]
- 15. Koury MJ. 1996. Progress in understanding erythropoiesis In: Smyth JF, Boogaerts MA, Ehmer BR‐M, editors. rhErythropoietin in cancer supportive treatment. New York: Marcel Dekker, Inc; p 1–12. [Google Scholar]
- 16. Frenkel EP, Bick RL, Rutherford CJ. 1996. Anaemia of malignancy. Haematol Oncol Clin North Am 10:861–873. [DOI] [PubMed] [Google Scholar]
- 17. Stenke L, Wallvik J, Celsing F, Hast R. 1993. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7:1324–1327. [PubMed] [Google Scholar]
- 18. Ludwig H, Fritz E, Letigeb C, et al. 1994. Prediction of response to erythropoietin treatment in chronic anaemia of cancer. Blood 84:1056–1063. [PubMed] [Google Scholar]
- 19. Cazzola M, Messinger D, Battistel V, et al. 1995. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non‐Hodgkin lymphoma: dose finding and identification of predictors of response. Blood 86:4446–4453. [PubMed] [Google Scholar]
- 20. Koury MJ, Bondurant MC. 1990. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248:378–381. [DOI] [PubMed] [Google Scholar]
- 21. Wu H, Liu X, Jaemisch R, Lodish HF. 1995. Generation of committed erythroid BFU‐E and CFU‐E progenitors does not require erythropoietin receptor. Cell 83:59–67. [DOI] [PubMed] [Google Scholar]
- 22. Beguin Y, Clemons G, Pootraku P, Fillet G. 1990. Quantitative assessment of erythropoiesis and functional classification of anaemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81:1067–1076. [PubMed] [Google Scholar]
- 23. Cazzola M, Ponchio L, Pedrotti C, et al. 1996. Prediction of response to recombinant human erythropoietin (rHuEpo) in anaemia of malignancy. Haematologica 81:434–441. [PubMed] [Google Scholar]